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provided it is propeObjectives: A sizeable percentage of individuals infected by HIV and on antiretroviral
therapy (ART) fail to increase their CD4þ T-cells to satisfactory levels. The percentage of
regulatory T-cells (Tregs) has been suggested to contribute to this impairment. This study
aimed to address this question and to expand the analysis of Tregs subpopulations
during ART.
Design: Longitudinal follow-up of 81 HIV-infected individuals during the first 24
months on ART.
Methods: CD4þ T-cell counts, Tregs percentages, and specific Tregs subpopulations
were evaluated at ART onset, 2, 6, 9, 12, 16, 20, and 24 months of ART (five individuals
had no Tregs information at baseline).
Results: The slope of CD4þ T-cell recovery was similar for individuals with moderate
andwith severe lymphopenia at ART onset. No evidencewas found for a contribution of
the baseline Tregs percentages on the CD4þ T-cell counts recovery throughout ART. In
comparison to uninfected individuals, Tregs percentages were higher at ART onset only
for patients with less than 200 cells/ml at baseline and decreased afterwards reaching
normal values. Within Tregs, the percentage of naive cells remained low in these
patients. Reduced thymic export and increased proliferation of Tregs vs. conventional
CD4þ T cells might explain these persistent alterations.
Conclusion: No effect of Tregs percentages at baseline was detected on CD4þ T-cell
recovery. However, profound alterations on Tregs subpopulations were consistently
observed throughout ART for patients with severe lymphopenia at ART onset.
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1176 AIDS 2016, Vol 30 No 8immune reconstitution in most patients [1]. However,
among the HIV-infected individuals that initiate ART
and become virologically suppressed for several years
(4–7 years), 15–40% fail to achieve a satisfactory CD4þ
T-cell reconstitution. These individuals are referred
to as immunological nonresponders [2]. The failure to
reconstitute the CD4þ T-cell counts might result
from insufficient production of new T cells and/or
insufficient division of the peripheral T cells, which may
be aggravated by continuous peripheral destruction of T
cells [3]. Several conditions, individually or in combi-
nation, might contribute to this defect (reviewed by
Gaardbo et al. [2] and by Corbeau et al. [4]): advanced age;
long periods of time between HIV infection and ART
initiation; bone marrow impairment to produce hema-
topoietic stem cells; impaired thymic function; enhanced
T-cell activation and/or apoptosis (mainly because of
residual viral replication, gut microbial translocation, or
coinfections by hepatitis C virus, cytomegalovirus, or
other herpes virus). Importantly, low CD4þ T-cell counts
at ART onset have consistently been shown as the
strongest predictor for poorer CD4þ T-cell recovery even
for virologically suppressed individuals.
The role of regulatory T cells (Tregs) in HIV-infection
pathogenesis has been extensively debated [5]. These cells
may play a beneficial role by dampening the immune
activation and suppressing HIV replication within
conventional CD4þ T cells (Tconv) [6,7]. Still, Tregs
may have a harmful role by impairing specific anti-HIV
immune response [8–11], inhibiting lymphopenia-
induced proliferation [12,13], contributing for gut
microbial translocation [14,15] and for exacerbated
lymphoid tissues’ fibrosis [16]. The dynamics of Tregs
during HIV infection have been the subject of several
studies. Most reports describe that Tregs percentages
among CD4þ T cells in ART-naı¨ve HIV-infected
individuals is higher than in healthy controls [17–22],
though others observed no differences [7,8,23]. The
percentage of Tregs during ART is also a controversial
issue, whereas most studies show that Tregs percentages
during ART tend to reach values similar to those in HIV-
uninfected controls [18,19,22,24–26], others claim its
maintenance above what is considered normal for healthy
controls [17,20,21,27]. The potential effect of Tregs on
the immune recovery of individuals on ART has also been
suggested. Although a few studies showed an association
between high Tregs percentages and lower CD4þ T-cell
numbers [3,12,25,28,29], the contribution of Tregs
percentages, at ARTonset, on the quality of the immune
reconstitution has not been established. The lack of
consensus between the various studies might relate to
diverse factors including the study design (cross-sectional
or longitudinal studies), the small number of patients in
most studies, the heterogeneity on the baseline CD4þ
T-cell counts at ART onset and the definition of Tregs
(please see supplementary Table S1, http://links.lww.
com/QAD/A891, for more detailed information onstudies addressing these questions). In an attempt to bring
some clarification to these important questions, we
considered of relevance to perform a longitudinal
study, encompassing a reasonable number of individuals,
followed carefully from ART onset, presenting
quite different levels of CD4þ T-cell counts at
baseline and for whom all samples were analysed with
the same protocol, being Tregs identified using the
most updated available and comprehensive set of markers
(CD25highCD127-FOXP3þ among CD4þCD3þ
lymphocytes) [30]. In accordance, we followed a cohort
of HIV-infected individuals from ART onset up to 24
months. In the analysis, several parameters that could be
confounders for the association between Tregs at baseline
and CD4þ T-cell recovery were considered.Materials and methods
Study population
Individuals included in this study were on medical care at
the Hospital Joaquim Urbano Unit/Centro Hospitalar do
Porto (HJUU/CHP), Portugal. Individuals were pro-
vided an explanation of the study and, from those who
agreed to participate, a signed informed consent was
obtained (Hospital Joaquim Urbano’s Ethical Committee
approval reference 168/CES, 2 October, 2009). Inclusion
criteria were: being over 18 years of age, infected with
HIV-1 (referred to as HIV, from now on), and ART-naive
but with criteria to initiate ART. Clinical information
and blood samples were collected at baseline
(i.e. immediately before ART initiation) and 2, 6, 9,
12, 16, 20, and 24 months afterwards. ART schemes
chosen (Supplementary Table 2, http://links.lww.com/
QAD/A891) for each individual took into consideration
characteristics of each individual, scientific policy, and
the national and international guidelines [31,32].
From the 96 individuals initially involved in the study,
81 (95% Caucasian) filled the requisites to be included in
the present work as they were therapy compliant for the
24 months (cohort characterization depicted in Supple-
mentary Table S2, http://links.lww.com/QAD/A891).
From the 81 individuals included in the study (Supple-
mentary Table S3, http://links.lww.com/QAD/A891),
no information regarding Tregs and its subpopulations at
baseline was available for five of them (AH006, AH037,
AH091, AH092 and AH093), two individuals presented
plasma viral loads above 50 copies/ml at 24 months after
ARTonset (AH054 and AH080) but were confirmed to be
virologically suppressed at 28 months, for four individuals,
the data relative to 28 months of follow-up were used
instead of the 24 months (three did not attend the
24 months-visit – AH014, AH031, and AH085 – and one
had pneumonia at this time point – AH030). A group of
age and sex-matched HIV-uninfected study participants,
living in the same region, was used as control (Supple-
mentary Table S2, http://links.lww.com/QAD/A891).
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Blood was collected and sent on the same day for routine
measurements (by a reference laboratory to assess CD4þ
T-cell count and HIV viral load) and for complementary
multiparametric flow cytometry analyses. Quantification
of Tregs was performed in peripheral blood mononuclear
cells and the evaluation of overall CD4þ T-cell activation
in whole blood, as previously described [25], using the
following anti-human monoclonal antibodies: anti-CD3
(OKT3 or UCHT1), anti-CD4 (RPA-T4), anti-CD8
(RPA-T8), anti-CD25 (BC96), anti-CD31 (WM59),
anti-CD45RA (HI100), anti-CD45RO (UCHL1), anti-
CD127 (clone AO19D5), anti-HLA-DR (L243), anti-
FOXP3 (PCH101), and anti-Ki67 (MOPC-21). Samples
were acquired on a BD LSRII flow cytometer using the
FACS DIVA v6.0 (BD Biosciences, San Jose, California,
USA) and data analysed using FlowJo vX.07 (TreeStar,
Ashland, Oregon, USA). The gating strategy is presented
on Supplementary Figure S1 (http://links.lww.com/
QAD/A891).
Statistical analysis
To evaluate the distribution of the variables, skewness,
and kurtosis values were calculated and normal distri-
bution was considered for variables with absolute values
of skewness below 3 and kurtosis below 8 [33]. Brown–
Forsythe test was used to evaluate equality of variances.
When the conditions of normality, equality of variances,
and other assumptions specific for each test were
observed, parametric tests were used; otherwise, the
nonparametric counterpart was chosen. Repeated
measures one-way analysis of variance (ANOVA) or
Friedman’s test, followed by Bonferroni’s or Dunn’s
multiple comparison tests respectively, were used to
perform repeated measures to evaluate the evolution of
Tregs percentages and CD4þ T-cell counts throughout
ART in comparison to baseline (Figs 1b and 2b). Two-
way ANOVA repeated measures followed by Sidak’s
multiple comparison tests were used to compare the
CD4þ T-cell counts throughout ART between individ-
uals with less than or at least 10% Tregs among CD4þ T
cells (Fig. 3). One-way ANOVA or Kurskall–Wallis test,
followed by Bonferroni’s or Dunn’s multiple comparison
tests respectively, were used to compare the CD4þ T-cell
slopes between the different CD4þT-cell strata at baseline
(Fig. 1c), the Tregs percentages of HIV-uninfected
individuals with that from the HIV-infected individuals
at different times of ART (Fig. 2a) and the percentage of
naı¨ve and proliferating Tregs and the recent thymic
emigrant Tregs counts (Fig. 4). As missing values are not
allowed on repeated measurements analyses (Figs 1c, 2b,
and 3), this limitation was surpassed by estimating the
missing values as the mean of the neighbour values
(estimated values represented 1.25 and 2.88% of all CD4þ
T-cell counts and Tregs percentages measurements,
respectively; Supplementary Table S3, http://links.lww.
com/QAD/A891, depicts the raw data where estimated
values are underlined). Importantly, the analysesperformed including and excluding individuals with
estimated values yielded similar results (Supplementary
Figures S2 and S3, respectively, http://links.lww.com/
QAD/A891).
To evaluate the predictors for the CD4þ T-cell counts at
24 months of ART, hierarchical linear regression models
were used. Independent variables were included in the
model when P< 0.20 on a preliminary univariate analysis
(Supplementary Table S4, http://links.lww.com/QAD/
A891).
Overall, tests were considered significant when P< 0.05
and denoted with ; no intertest adjustments of the
P-value were performed. As a measure of the magnitude
of a difference, effect size (practical significance), was
calculated as follows [34]: for the one-way ANOVA (both
ordinary and repeated measures) the eta square (h2) was
calculated as the ratio of the between-groups sum of
squares (SSbtw) and the total SS (SStot; h
2¼ SSbtw/ SStot);
for the Kruskal–Wallis test, h2 (h2KW) was calculated as
the ratio of x2 and the number of individuals (n) minus
1 [h2KW¼x2/(n 1)]; for the two-way ANOVA
repeated measures the partial h2 (h2P) was calculated as
the ratio of the SSbtw and the sum of the SSbtw and the
residual SS [SSres; h
2
P¼ SSbtw/(SSbtwþ SSres)]; for the
Friedman’s test, Kendal’s W (WK) was calculated as the
ratio of x2 and the number of groups (k) times n - 1
(WK¼x2/[k(n - 1)]); finally for the unpaired T-test
Cohen’s d was calculated as the ratio of the means’
difference (M) over the square root of the SD sum over
two [d¼ (M1M2)/SQR[(SD1þ SD2)/2]]. For h2, h2P,
and h2KW, a small effect size was considered for values
between at least 0.01 and less than 0.06, medium between
at least 0.06 and less than 0.14, and a large effect size at
least 0.14; for theKW, a small effect size was considered for
values between at least 0.1 and less than 0.3, medium
between at least 0.3 and less than 0.5 and a large effect
size when at least 0.5; for d a small effect size was
considered for values between at least 0.2 and less than
0.5, medium between at least 0.5 and less than 0.8, and a
large effect size when at least 0.8.
Statistical analyses were performed using the SPSS v22
(IBM Corporation, Armonk, New York, USA) and the
GraphPad Prism v6 (GraphPad Software, La Jolla,
California, USA).Results
Regulatory T-cell percentages dynamics during
antiretroviral therapy varied accordingly to the
baseline CD4R T-cell counts
The ART regimens used resulted, as expected, in an
overall rapid and strong decline of the plasma viral load
for all individuals (Supplementary Figure S4, http://
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Fig. 1. CD4R T-cell counts increase rate was similar between individuals with quite distinct CD4R T-cell counts at baseline. (a)
CD4þ T-cell progression for three-defined CD4þ T-cell strata. The median of each time point is represented for the three strata
independently. (b) The evolution of the CD4þ T-cell counts throughout ART is represented for each individual (thin black lines) and
for the median of all the individuals (thick green line). The evolution of CD4þ T-cell counts with ARTwas evaluated using one-way
ANOVA repeated measures followed by Bonferroni’s multiple comparison tests using as reference group the ART-naive
individuals: <200 F (32, 192)¼17.59, P<0.0001, h2¼0.326; 200–350: F (32, 192)¼10.83, P<0.0001, h2¼0.275; and
>350: F (14, 84)¼17.64, P< 0.0001, h2¼0.140. (c) Comparison of the rates of CD4þ T-cell recovery during the 24months of ART
between the three-defined strata. Slopes were calculated by the least squares estimation method [25]. Each dot represents a single
individual and the solid horizontal line the mean. Comparisons were performed using a Kruskal–Wallis test followed by Dunn’s
multiple comparison tests; no statistical significant differences were observed (X2KW (2, 78)¼0.528 P¼0.7681, h2KW¼0.264).
ART, antiretroviral therapy; M, months.links.lww.com/QAD/A891) and in an overall significant
increment of the CD4þ T-cell counts (Fig. 1a and b). No
significant differences were observed on the CD4þ T-cell
slope between individuals with distinct CD4þ T-cell
count at ARTonset (<200, 200–350, and>350 CD4þT
cells/ml; Fig. 1c), in accordance with previously
published reports [31,35].
Tregs were defined as the CD127lowCD25highFOXP3þ
cells among CD4þ T cells (CD3þCD4þ), following the
work of Sakaguchi and collaborators [30] and using the
gating strategy previously described [25] depicted in
Supplementary Figure S1 (http://links.lww.com/QAD/
A891). To determine whether Tregs percentages
evolution throughout therapy differed accordingly to
the disease stage at ARTonset, individuals were stratified
based on the baseline CD4þ T-cell counts (<200, 200–
350, and >350 CD4þ T cells/ml). Interestingly, thedifferences observed on Tregs percentages between
healthy controls and the overall HIV-infected individ-
uals, or between baseline and the different time-points
after ARTonset, were particularly evident for individuals
with very low CD4þ T-cell counts at baseline
(<200 cells/ml; Fig. 2a and b). In addition, the group
of patients with the lowest baseline CD4þ T-cell counts
presented also a greater variability on the Tregs
percentages, variance analysis revealed that it was
unequal along the different time points among these
individuals [F(8, 286)¼ 5.214, P< 0.0001, Brown–
Forsythe test], but not for individuals with greater than
200 CD4þ T cells/ml at baseline [200–350: F(8,
292)¼ 1.895, P¼ 0.0605; >350: F(8, 152)¼ 0.866,
P¼ 0.5467, Brown–Forsythe test (Fig. 2a)]. Notwith-
standing the increased percentage of Tregs on HIV-
infected individuals, the absolute numbers of Tregs were
lower than in uninfected individuals throughout the
Regulatory T-cell dynamics in HIV patients Nobrega et al. 1179
%
 o
f T
re
gs
 a
m
on
g 
CD
4+
 
T 
ce
lls
%
 o
f T
re
gs
 a
m
on
g 
CD
4+
 
T 
ce
lls
%
 o
f T
re
gs
 a
m
on
g 
CD
4+
 
T 
ce
lls
%
 o
f T
re
gs
 a
m
on
g 
CD
4+
 
T 
ce
lls
%
 o
f T
re
gs
 a
m
on
g 
CD
4+
 
T 
ce
lls
%
 o
f T
re
gs
 a
m
on
g 
CD
4+
 
T 
ce
lls
<200 CD4+ T cells/µl @ 0M
(a) (b)
*
*
* *
*
*
HIV– 0M
(28)
2M
(32)
6M
(32)
9M
(31)
12M
(30)
16M
(33)
20M
(32)
24M
(33)
HIV– 0M
(33)
2M
(30)
6M
(33)
9M
(33)
12M
(30)
16M
(33)
20M
(32)
24M
(33)
HIV– 0M
(15)
2M
(14)
6M
(15)
9M
(15)
12M
(15)
16M
(15)
20M
(13)
24M
(15)
60
30
30
20
10
0
60
30
30
20
10
0
0 2 6 9 12 16 20 24
0 2 6 9 12 16 20 24
0 2 6 9 12 16 20 24
60
30
30
20
10
0
60
30
30
20
10
0
60
30
30
20
10
0
60
30
30
20
10
0
200-350 CD4+ T cells/µl @ 0M
>350 CD4+ T cells/µl @ 0M
Time on ART
(number of individuals)
Time on ART (months)
>350 CD4+ T cells/µl @ 0M (n = 15)
200-350 CD4+ T cells/µl @ 0M (n = 33)
<200 CD4+ T cells/µl @ 0M (n = 28)
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patients. (a) Tregs percentages of healthy controls and HIV-infected individuals stratified according to their CD4þ T-cell counts at
baseline. Each dot represents a single individual, the horizontal black line represents the group’s median, and the shaded green
horizontal bar represents the range of Tregs percentages among CD4þ T cells described for healthy individuals using similar
markers [8]. Comparisons were performed using an one-way ANOVA or a Kruskal–Wallis test, followed by Bonferroni’s or Dunn’s
multiple comparison tests, respectively, using as reference group the HIV-uninfected individuals: <200: X2KW (8, 286)¼34.590,
P<0.0001, h2KW¼0.118; 200–350: F (8,292)¼1.895, P¼0.0605, h2¼0.049; and >350: F (8, 152)¼ 1.759, P¼0.0894,
h2¼0.085. (b) Stratification of HIV-infected individuals according to CD4þ T-cell counts at baseline and longitudinal evaluation
of Tregs percentages throughout the first 24 months of ART. Each thin black line represents the Tregs percentages evolution of a
single individual and the bold black line represents the median of the individuals for each time point. The evolution of Tregs
percentages with ART was evaluated using Friedman’s test followed by Dunn’s multiple comparison tests using as reference group
the ART-naive individuals:<200: X2F (7)¼27.91, P¼0.0002, n¼28,WK¼0.129; 200–350: X2F (7)¼23.19, P¼0.0016, n¼33,
WK¼0.091; and >350: X2F (7)¼20.43, P¼ 0.0047, n¼ 15, WK¼0.182. ART, antiretroviral therapy; M, months.whole follow-up period for individuals with less than 350
CD4þ T cells/ml at ART onset (Supplementary Figure
S5A, http://links.lww.com/QAD/A891). Interestingly,
at ART onset, the ratio between Tconv and Tregs was
significantly lower for individuals with less than200 CD4þ T cells/ml when compared to uninfected
individuals (Supplementary Figure S5B, http://
links.lww.com/QAD/A891), suggesting an increased
loss of Tconv, in comparison to Tregs, in patients with
severe lymphopenia.
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baseline were associated, per se, with the progression of
CD4þ T-cell counts throughout ART. For that purpose,
individuals were stratified according to their Tregs
percentage at baseline (less than or at least 10%, as
defined in [25]) and the CD4þ T-cell counts were
evaluated throughout therapy. Globally, individuals with
higher baseline Tregs percentages had lower CD4þ T-cell
counts at baseline (209 151 vs. 324 237 cells/ml,
t¼ 2.503, P¼ 0.0150, d¼ 0.578, unpaired T-test with
Welch’s correction), but no differences were detected on
the overall CD4þ T-cell reconstitution between individ-
uals with lower and higher Tregs percentage even when
patients were stratified accordingly to their CD4þ T-cell
counts at baseline (Fig. 3). As several factors are known to
influence the immune reconstitution (e.g. age, sex, basal
viral load, residual viral replication during ART,
coinfections, immune activation status [4]), hierarchical
linear regression models were computed to dissect
whether Tregs percentages at baseline could represent
an additional contributor to predict CD4þ T-cell
recovery. Age, sex, coinfections, viral loads at baseline
and at 24 months and immune activation status (HLA-
DRþ cells among CD4þ T cells) at 24 months of ART,
were able to significantly predict 25% of the CD4þ T-cell
counts at 24 months of ART (Table 1, model 1). When
the Tregs percentages at baseline were included in the
model (Table 1, model 2) the predictive capacity of the
model increased to 31%, with Tregs percentages at
baseline being a significant predictor of CD4þ T-cell
reconstitution. Taking all the aforementioned variables in
consideration, for the gain of each percentage unit of
Tregs at baseline, the predicted CD4þ T-cell counts at
24 months decreased by 12.7 cells/ml. When the CD4þ
T-cell counts at baseline were included in the analysis
(Table 1, model 3) the predictive value of the model raisedto 66% and the contribution of the baseline Tregs
percentages lost its significance. These analyses, con-
sidering several factors known to effect CD4þ T-cell
counts reconstitution did not reveal an additional effect of
Tregs percentages at baseline on CD4þ T-cell counts at
24 months of ART.
HIV-infected individuals presented regulatory T-
cell subset disturbances that were not restored
with antiretroviral therapy
Tregs functionality is assured not only by their numbers
and proportions, in respect to the total CD4þ T cells, but
also by the maintenance of the right proportion of their
subpopulations. Tregs can be subdivided in naive
(CD45RAþ) and memory Tregs (CD45RA-), which
are developmentally related subsets with distinct pheno-
types [30,36]. We observed clear disturbances in Tregs
subpopulations distribution; in ART-naive HIV-infected
individuals the percentage of CD45RAþ cells among
total Tregs was lower than in healthy individuals, and this
difference persisted even after 24 months of ART
especially for individuals with less than 200 CD4þ
T cells/ml at baseline (Fig. 4a). As most naı¨ve Tregs are
generated in the thymus, they express high levels of
CD31, which is a marker for recent thymic emigrants
[30,37]. To understand whether the impairment on the
recovery of the CD45RAþ Tregs population was
associated with lower thymic output, we quantified
CD45RAþ Tregs expressing high levels of CD31
(CD45RAþCD31hi Tregs), which should reflect blood’s
Tregs most recently exported from the thymus [38,39].
We observed that the CD45RAþCD31hi Tregs counts
were consistently lower in HIV-infected patients with
CD4þ T-cell counts less than 350 cells/ml, irrespective of
their time on ART, in comparison to uninfected
individuals (Fig. 4b). Interestingly, a significant increase
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Table 1. Hierarchical linear regression models to predict CD4R T-cell counts at 24 months of antiretroviral therapy.
Model 1 Model 2 Model 3
B SE b P B SE b P B SE b P
Agea 5.18 2.74 0.20 0.06 7.17 2.74 0.27 0.01M 3.40 1.97 0.13 0.09
Sexb 44.35 66.28 0.07 0.51 79.59 64,87 0.13 0.22 27.57 47.27 0.04 0.56
Log (HIV viral load) @ 0M 113.09 43.82 0.28 0.01M 97.49 42.39 0.24 0.02M 23.36 31.03 0.06 0.45
Log (HIV viral load) @ 24M 393.25 184.99 0.16 0.12 331.55 177.75 0.19 0.07 48.42 129.18 0.03 0.71
Chronic comorbilityc 76.66 62.01 0.13 0.22 46.54 60.48 0.08 0.44 100.78 42.87 0.18 0.02M
HLA-DRþ among CD4þ T cells @ 24M 7.00 1.81 0.43 0.00M 7.14 1.73 0.43 0.00M 2.72 1.33 0.17 0.04M
%Tregs cells @ 0M     12.70 4.84 0.28 0.01M 0.47 3.75 0.01 0.90
CD4þ T-cell count @ 0M         0.80 0.11 0.72 0.00M
F (dF1, dF2) 4.86 (6, 65)M 5.53 (7, 64)M 18.29 (8, 63)M
R2adjusted 0.25 0.31 0.66
R2adjusted change  0.06 0.41
Selection of the variables to be included in themodelswas based on the literature [4] and on the univariate analysis (Table S4, http://links.lww.com/
QAD/A891).
aAt baseline.
bReference category: women (n¼18).
cReference category: no chronic comorbidity (HCV infection/cancer/medical condition leading to recurrent infections; consider positive when at
least one of them occurred during the 24 months of ART; n¼22).
Variables were considered to significantly contribute to the model when P<0.05 and represented by M.from baseline was observed for CD45RAþCD31hi Tconv
counts but not for CD45RAþCD31hi Tregs (Supple-
mentary Figure S6, http://links.lww.com/QAD/A891),
suggesting a stronger contribution of the thymus for the
recovery of Tconv than for that of Tregs.
As for the percentage of Tregs undergoing proliferation,
only patients with the lowest CD4þ T-cell counts at
baseline (less than 200 cells/ml) presented significantly
higher proportions of Ki67þ Tregs when compared to
healthy individuals and these differences were maintained
until the end of follow-up (Fig. 4c). Importantly, most of
the Tregs undergoing proliferation had, as expected, a
memory phenotype (Supplementary Figure S7, http://
links.lww.com/QAD/A891). As shown by others,
although in the context of allogeneic hematopoietic
stem cell transplantation [40], we observed that the
proportion of Ki67þ cells among Tregs was consistently
higher than among Tconv, both for uninfected controls
and for HIV-infected individuals, resulting in a ratio of
Tregs Ki67þ/Tconv Ki67þ cells around 5. Of relevance,
this ratio was lower in HIV-uninfected vs. infected
individuals with up to 6 months of ART (Supplementary
Figure S8, http://links.lww.com/QAD/A891).Discussion
The evolution of the percentage of total Tregs and that
of Tregs subpopulations during ART, as well as their
association with the immune reconstitution of HIV-
infected individuals, are still controversial issues that
merits attention. As an attempt to add evidence that
could bring consensus to this matter, we performed a
longitudinal study of HIV-infected individuals followed
at specific time points for 24 months upon ART onset.This study is unique and important to complement
previous published work, since it is longitudinal and
encompasses 81 individuals, all followed from the
day they initiated ART, and from whom Tregs were
identified as CD127lowCD25highFOXP3þ cells among
CD4þCD3þ lymphocytes (for comparison with
previous studies please see Supplementary Table S1,
http://links.lww.com/QAD/A891). If we take into
consideration that a key feature of HIV infection is the
immune hyperactivation [41], the usage of this complete
set of markers to identify Tregs is pivotal to clearly
discriminate Tregs from activated Tconv given that
activation of Tconv might lead to the upregulation of
CD25 and downregulation of CD127; FOXP3 is not
exclusive from Tregs; and CD127 and FOXP3 allow a
better definition of the boundary between CD25int and
CD25hi cells [30]. To our knowledge, only one
additional longitudinal study to date used this complete
set of Tregs markers though with a somewhat smaller
sample size (n¼ 11 patients on ART) [22]. An additional
advantage of the present study relies on the fact that the
enrolled patients presented quite distinct baseline CD4þ
T-cell counts. This allowed us to follow, for distinct
baseline CD4þ T-cell counts the dynamics of Tregs and
of its subpopulations throughout ART, and to evaluate
the potential combined effect of baseline Tregs
percentages and CD4þ T-cell counts on the overall
immune recovery.
The Tregs percentage of ART-naive HIV-infected
individuals was found to be higher than that of healthy
controls, as reported previously by others [17–22]. Our
study, by including a greater number of individuals with
quite varied baseline CD4þ T-cell counts at ARTonset,
clearly shows that, despite the overall higher percentage
of Tregs, there is a substantial heterogeneity in the Tregs
percentages among HIV-infected patients. Interestingly,
1182 AIDS 2016, Vol 30 No 8
<200 CD4+ T cells/µl @ 0M
(a) (b) (c)
200-350 CD4+ T cells/µl @ 0M
HIV– 0M
(20)
2M
(22)
6M
(24)
9M
(26)
12M
(25)
16M
(28)
20M
(27)
24M
(28)
HIV– 0M
(16)
2M
(19)
6M
(28)
9M
(33)
12M
(30)
16M
(33)
20M
(32)
24M
(33)
HIV– 0M
(10)
2M
(10)
6M
(15)
9M
(15)
12M
(15)
16M
(15)
20M
(13)
24M
(15)
HIV–
(31)
0M
(11)
2M
(9)
6M
(13)
12M
(15)
16M
(15)
20M
(13)
24M
(15)
HIV–0M
(5)
2M
(7)
6M
(11)
9M
(15)
12M
(15)
16M
(15)
20M
(13)
24M
(15)
HIV– 0M
(13)
2M
(13)
6M
(21)
9M
(27)
12M
(30)
16M
(33)
20M
(32)
24M
(33)
HIV–
(31)
0M
(16)
2M
(17)
6M
(28)
12M
(29)
16M
(33)
20M
(31)
24M
(31)
HIV–
(31)
0M
(21)
2M
(25)
6M
(27)
12M
(30)
16M
(33)
20M
(32)
24M
(30)
HIV– 0M
(17)
2M
(21)
6M
(26)
9M
(26)
12M
(30)
16M
(33)
20M
(32)
24M
(32)
>350 CD4+ T cells/µl @ 0M
%
 C
D4
5R
A+
 
a
m
o
n
g 
Tr
e
gs
CD
31
hi
CD
45
RA
+
 
Tr
e
gs
 c
o
u
n
ts
(ce
lls
/µL
)
CD
31
hi
CD
45
RA
+
 
Tr
e
gs
 c
o
u
n
ts
(ce
lls
/µl
)
CD
31
hi
CD
45
RA
+
 Tr
e
gs
 c
ou
nt
s
(ce
lls
/µl
)
%
 K
i6
7+
 
a
m
o
n
g 
Tr
e
gs
%
 K
i6
7+
 
a
m
o
n
g 
Tr
e
gs
%
 K
i6
7+
 
a
m
o
n
g 
Tr
e
gs
%
 C
D4
5R
A+
 
a
m
o
n
g 
Tr
e
gs
%
 C
D4
5R
A+
 
a
m
o
n
g 
Tr
e
gs
Time on ART
(number of individuals)
Time on ART
(number of individuals)
Time on ART
(number of individuals)
>350 CD4+ T cells/µl @ 0M >350 CD4+ T cells/µl @ 0M
200-350 CD4+ T cells/µl @ 0M 200-350 CD4+ T cells/µl @ 0M
<200 CD4+ T cells/µl @ 0M <200 CD4+ T cells/µl @ 0M
60
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
50
40
30
20
10
0
10 60
50
40
30
20
10
0
60
50
40
30
20
10
0
60
50
40
30
20
10
0
8
6
4
2
0
10
8
6
4
2
0
10
8
6
4
2
0
60
50
40
30
20
10
0
60
50
40
30
20
10
0
Fig. 4. Individuals with severe lymphopenia at baseline maintain throughout ART low percentage of Tregs with a naive
phenotype and impaired production of Tregs by the thymus. (a) Percentage of CD45RAþ cells among Tregs upon stratification of
the individuals accordingly to their CD4þ T-cell counts at baseline. (b) Numbers of Tregs recent thymic emigrants
(CD45RAþCD31hi) upon stratification of the individuals accordingly to their CD4þ T-cell counts at baseline. (c) Percentage
of Ki67þ cells among Tregs upon stratification of the individuals accordingly to their CD4þ T-cell counts at baseline. In all graphs,
each dot represents a single individual and the horizontal lines represent the median. Comparison between healthy controls and
HIV-infected individuals at ART onset or on different time points upon ART initiation was performed using an one-way ANOVA or
a Kruskal–Wallis test followed by Bonferroni’s or Dunn’s multiple comparison tests, using as reference group the uninfected
individuals: (a)<200: F (8, 246)¼8.70, P<0.0001, h2¼0.221; 200–350: F (8, 262)¼1.91, P¼0.0585, h2¼0.055; and>350: F
(8, 144)¼0.63, P¼0.7554, h2¼0.034; (b) <200: X2KW (7, 221)¼ 43.52, P<0.0001, h2KW¼0.191; 200–350: F (7, 208)¼2.50,
P¼ 0.0173, h2¼0.078; and >350: F(7, 114)¼0.29, P¼0.9576, h2¼ 0.017; (c) <200: X2KW (8, 152)¼ 37.64, P<0.0001,
h2KW¼0.145; 200–350: F (8, 237)¼1.32, P¼0.2362, h2¼0.043; and >350: F (8, 131)¼0.61, P¼0.7714, h2¼0.036. ART,
antiretroviral therapy; M, months.the group of individuals with the lowest CD4þ T counts
at baseline was noticeably enriched with patients with
the higher Tregs percentages. These findings may justify
why some previous studies suggested that Tregspercentages are similar between ART-naive HIV-
infected individuals and healthy controls [8,23], since
they encompassed mostly patients with moderate
lymphopenia.
Regulatory T-cell dynamics in HIV patients Nobrega et al. 1183Several reports indicated a role for Tregs on the
accomplishment of a successful immune reconstitution
[3,12,25,28,29]. Individuals with impaired immune
reconstitution (i.e., less than 500 CD4þ T cells/ml after
1–15 years of ART) were shown to have the highest Tregs
percentages (>10%) and lowest nadir values (the lowest
CD4þ T-cell count achieved by each HIV-infected
individual) [25]. Another study, that included multi-
variate analysis adjusted for age, nadir, Tregs percentages
and CD8þT-cell activation, suggested that low nadirs and
high Tregs percentages during ARTwere associated with
inadequate immunological response [28]. All the above
mentioned studies evaluated the impact of Tregs
percentages during ART. The hierarchical linear
regression model presented herein showed that the
percentage of Tregs at baseline had no predictable
impact on the CD4þ T-cell recovery until up to 24
months of ART. This observation contrasts with the
recent work published by Saison and collaborators [26].
In that study, the authors claim that the Tregs percentages
at baseline are a strong independent prognostic factor of
immune recovery, particularly for the individuals with
low nadir [26]. Part of these discrepancies may be
explained by the used of different criteria to define
Tregs, whereas, Saison and collaborators define Tregs as
CD4þCD25þCD127-, and we defined these cells as
CD127lowCD25highFOXP3þ cells among CD4þ T cells.
Additionally, the model in the present study also adjusts
for peripheral T-cell activation (HLA-DRþ among
CD4þT cells), which, as expected, was a strong predictor
of immune reconstitution.
Despite the fact that some reports showed no alterations
on the suppressive capacity of Tregs during HIV-infection
[42], recent data reported that Tregs infected in vitro by
HIV have impaired suppressive capacity and decreased
expression of critical genes for Tregs function [43,44].
Though no information on individuals’ Tregs suppressive
function is available in the present study, which is a
weakness, one could envisage that the previously reported
impaired suppressive capacity could explain why indi-
viduals with high Tregs percentages at baseline had no
increased difficulties in recovering their CD4þ T-cell
counts. In accordance, we observed that Tregs percen-
tages at baseline positively correlates with the percentage
of CD4þ T cells with an activated phenotype
(HLA-DRþ) and undergoing proliferation (Ki67þ; data
not shown). Future in-vitro studies are needed to evaluate
Tregs’ suppressive capacity from individuals with high and
low baseline Tregs percentages.
Disturbances on Tregs subsets homeostasis in ART-naive
HIV-infected individuals have been described in several
studies [3,8,29,45–47]. Some of these evaluated the
percentage of Tregs subsets among CD4þ T cells [8,46].
However, because the percentage of total Tregs among
CD4þ T cells is highly variable within HIV-infected
individuals, looking at Tregs subsets percentages in respectto total CD4þ T cells, and not specifically in the context
of Tregs, might limit data interpretation. Taking into
account only the studies that measured naive cells among
Tregs cells, the one by Gaardbo and collaborators showed
a lower percentage of naive cells in HIV-infected
individuals on ART, when compared to uninfected
individuals, irrespectively from the patients’ immune
reconstitution outcome [47]. On the contrary, Serana and
collaborators observed no significant differences on this
Tregs subset percentage in healthy controls vs. individuals
on ART for more than 6 years [45]. The discrepancy
between these results might now be justified, as we
observed that the evolution of the naive cells proportion
among Tregs varies according to the CD4þ T-cell counts
at baseline.
Naive Tregs are mostly composed by natural Tregs, which
are generated in the thymus [30,37] that is known to be
affected by HIV infection [39,48,49]. The proportion of
naive Tregs depends on the balance between the newly
generated naive Tregs and those that through activation/
proliferation are converted into activated Tregs. By
quantifying recent thymic emigrant Tregs (i.e. Tregs that
express CD45RAþCD31hi), we show here that, while
there was a general increase in the number of
CD45RAþCD31hi Tconv, the recent thymic emigrant
Tregs counts in HIV-infected individuals on ART was
consistently lower than the one of uninfected controls,
and remained unaltered throughout ART. These results
suggest that the decreased proportion of Tregs, observed
during ART, might in part result from a proportionally
decreased production of Tregs by the thymus, which
might also impact on the decreased percentage of naive
Tregs. Notwithstanding, we observed, as others [40],
higher proportions of Ki67þ cells among Tregs in
comparison to Tconv. Of interest, the ratio Tregs Ki67þ/
Tconv Ki67þ was found decreased in HIV-infected
patients from baseline up to 6 months on ART. The fact
that the number of CD45RAþCD31hi Tregs was
maintained consistently lower suggests that an impaired
production of Tregs by the thymus is, at least in part,
responsible for the sustained decreased proportion of
naı¨ve Tregs among total Tregs, although cell division
might also contribute.
Taken together, our data shows that the evolution of Tregs
percentages and of Tregs subpopulations during ART
varies greatly according to the lymphopenia level at
baseline. Whereas the Tregs percentages were signifi-
cantly higher than that of the control individuals for
more lymphopenic patients, this was not observed for
individuals initiating ART with CD4þ T-cell counts
greater than 350 cells/ml. In addition, individuals with
very low CD4þ T-cell counts at baseline displayed high
diversity on the Tregs percentages. These observations
conciliate some controversial data reported in the
literature. The present study also shows that, throughout
ART, although Tregs percentages may reach values similar
1184 AIDS 2016, Vol 30 No 8to uninfected individuals, the proportion of naı¨ve cells
among Tregs tend to be consistently low. A reduced
export of Tregs by the thymus might be responsible for
this, though a role for the increased activation/turnover of
naive and the consequent acquisition of a memory
phenotype should also be considered.
The reported results strengthen the idea that very low
baseline CD4þ T-cell counts leads to disruptions of
different immune populations, in addition to other severe
conditions induced by low CD4þ T-cell counts [50], and
that ART cannot counteract part of these alterations. The
individuals analysed in the present work should be
followed for longer periods to clearly define the potential
role of Tregs, and of other cell subsets, on the quality of
the immune reconstitution of HIV-infected individuals
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